• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Anika Therapeutics Inc.

Anika tops sales, EPS estimates with Q2 results

July 25, 2018 By Sarah Faulkner

Anika Therapeutics

Anika Therapeutics (NSDQ:ANIK) reported its second-quarter financial results today, topping sales and earnings estimates on Wall Street. The Bedford, Mass.-based company posted profits of $10 million, or 69¢ per share, on sales of $30.5 million for the 3 months ended June 30, for bottom-line loss of -11% on sales loss of -9% compared with the same […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Orthopedics, Pharmaceuticals, Wall Street Beat Tagged With: Anika Therapeutics Inc.

Anika shares plummet after Phase III trial misses endpoint

June 21, 2018 By Sarah Faulkner

Anika Therapeutics

Shares in Anika Therapeutics (NSDQ:ANIK) fell more than -30% this week after the company reported that its osteoarthritis drug, Cingal, failed in a Phase III trial. The therapy, designed to treat osteoarthritis of the knee, is a combination of cross-linked hyaluronic acid and triamcinolone hexacetonide. The trial’s primary endpoint compared the pain reduction experienced by patients […]

Filed Under: Clinical Trials, Featured, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Anika Therapeutics Inc.

Anika swings to a loss in Q1

May 3, 2018 By Sarah Faulkner

Anika Therapeutics

Shares in Anika Therapeutics (NSDQ:ANIK) fell in premarket activity today after the company missed expectations on Wall Street with its first-quarter results. The Bedford, Mass.-based company swung to a net loss of -$6.7 million, or -46¢ per share, on sales of $21.3 million for the 3 months ended March 31, down -9.1% compared with the same […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Orthopedics, Pharmaceuticals, Wall Street Beat Tagged With: Anika Therapeutics Inc.

Anika CEO retires after two decades; president assumes corner office | Personnel Moves – March 13, 2018

March 13, 2018 By Sarah Faulkner

Anika Therapeutics

Anika Therapeutics (NSDQ:ANIK) announced this month that CEO Charles Sherwood plans to retire after working for Anika for nearly twenty years. Joseph Darling, who has been Anika’s president since July 2017, will take his place in the corner office. Darling has previously served in executive leadership roles across an array of medtech companies like Abbott (NYSE:ABT), Baxter (NYSE:BAX) […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: abbott, alucentmedical, Anika Therapeutics Inc., Baxter, BioTime, Brainstorm Cell Therapeutics, Kala Pharmaceuticals, medherant, milestonescientific, pertinaxpharma, smith&nephew, West Pharmaceutical Services

Anika posts mixed Q4, FY17 results

February 22, 2018 By Sarah Faulkner

Anika Therapeutics

Shares in Anika Therapeutics (NSDQ:ANIK) rose today after the company topped earnings expectations on Wall Street with its fourth quarter and full-year financial results, but missed sales estimates. The Bedford, Mass.-based company posted profits of $8.1 million, or 55¢ per share, on sales of $29.3 million for the 3 months ended Dec. 31, for bottom-line loss […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Orthopedics, Pharmaceuticals, Wall Street Beat Tagged With: Anika Therapeutics Inc.

Anika collabs to develop injectable stem cell therapy for osteoarthritis

February 2, 2018 By Sarah Faulkner

Anika Therapeutics

Anika Therapeutics (NSDQ:ANIK) has inked an agreement with the Institute of Integrative Biology at the University of Liverpool to develop an injectable mesenchymal stem cell therapy to treat osteoarthritis. As a result of the three-year research collaboration, the group hopes to have a lead candidate that it can take into clinical trials. “We are very excited […]

Filed Under: Drug-Device Combinations, Featured, Orthopedics, Pharmaceuticals, Stem Cells, Wall Street Beat Tagged With: Anika Therapeutics Inc., University of Liverpool

Anika extends deal with UMass Amherst to develop rheumatoid arthritis therapy

January 25, 2018 By Sarah Faulkner

Anika Therapeutics

Anika Therapeutics (NSDQ:ANIK) has inked a deal to extend its two-year-long collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst. The group plans to focus its efforts on developing a novel therapeutic candidate to treat rheumatoid arthritis. Anika and UMass reported that it hopes to bring the product into clinical trials […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: Anika Therapeutics Inc.

Anika Therapeutics wins FDA nod for bone void filler

December 27, 2017 By Brad Perriello

Anika Therapeutics

Anika Therapeutics (NSDQ:ANIK) said today that it won 510(k) clearance from the FDA for its hyaluronic acid-based bone void filler The indication covers filling bone voids or defects that aren’t intrinsic to the stability of the bone, created during surgery or the result of traumatic injury. Made of a synthetic, biocompatible bone graft substitute material, […]

Filed Under: Featured, Food & Drug Administration (FDA), Orthopedics, Regulatory/Compliance Tagged With: Anika Therapeutics Inc.

OncoSec Medical names new CEO | Personnel Moves – Nov. 9, 2017

November 9, 2017 By Sarah Faulkner

OncoSec Medical

OncoSec Medical (NSDQ:ONCS)  announced earlier this week that the company’s co-founder, Punit Dhillon, would step down as CEO and continue to serve as president while Daniel O’Connor takes over the corner office. O’Connor joined OncoSec’s board of directors in September this year. “We are pleased to welcome Dan to OncoSec at this important time, and believe […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, Anika Therapeutics Inc., bostonbiomedical, Brainstorm Cell Therapeutics, DelMar Pharmaceuticals, Express Scripts, GlaxoSmithKline plc, OncoSec Medical, Pulmatrix Inc.

Anika misses revenue, earnings estimates in Q3

October 26, 2017 By Sarah Faulkner

Anika Therapeutics

Anika Therapeutics (NSDQ:ANIK) missed expectations on Wall Street with its third quarter results, the company reported yesterday after the market closed. The Bedford, Mass.-based company posted profits of $14.6 million, or 47¢ per share, on sales of $27.2 million for the 3 months ended Sept. 30, for a bottom-line loss of -0.3% on sales growth of […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Orthopedics, Wall Street Beat Tagged With: Anika Therapeutics Inc.

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS